The $9.7 billion Novartis deal turns on a quirk of how drugs are paid for in the U.S.: Insurers have less control over drugs given in hospitals than pharmacies via
I think the acquisition is also sending a clear signal that is not afraid of transforming itself by investing heavily in very innovative therapeutic approaches (siRNA here) via